226 related articles for article (PubMed ID: 31240602)
1. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice.
Velazquez R; Meechoovet B; Ow A; Foley C; Shaw A; Smith B; Oddo S; Hulme C; Dunckley T
Mol Neurobiol; 2019 Dec; 56(12):8364-8375. PubMed ID: 31240602
[TBL] [Abstract][Full Text] [Related]
2. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
[TBL] [Abstract][Full Text] [Related]
3. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
4. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
[TBL] [Abstract][Full Text] [Related]
5. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
6. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
Souchet B; Audrain M; Billard JM; Dairou J; Fol R; Orefice NS; Tada S; Gu Y; Dufayet-Chaffaud G; Limanton E; Carreaux F; Bazureau JP; Alves S; Meijer L; Janel N; Braudeau J; Cartier N
Acta Neuropathol Commun; 2019 Mar; 7(1):46. PubMed ID: 30885273
[TBL] [Abstract][Full Text] [Related]
8. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
[TBL] [Abstract][Full Text] [Related]
10. Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
Jin N; Yin X; Gu J; Zhang X; Shi J; Qian W; Ji Y; Cao M; Gu X; Ding F; Iqbal K; Gong CX; Liu F
J Biol Chem; 2015 Jun; 290(24):15219-37. PubMed ID: 25918155
[TBL] [Abstract][Full Text] [Related]
11. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
12. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
13. Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer's Disease.
Wang ZH; Liu P; Liu X; Manfredsson FP; Sandoval IM; Yu SP; Wang JZ; Ye K
Mol Cell; 2017 Sep; 67(5):812-825.e5. PubMed ID: 28826672
[TBL] [Abstract][Full Text] [Related]
14. Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation.
Scholtzova H; Chianchiano P; Pan J; Sun Y; Goñi F; Mehta PD; Wisniewski T
Acta Neuropathol Commun; 2014 Sep; 2():101. PubMed ID: 25178404
[TBL] [Abstract][Full Text] [Related]
15. DYRK1A inhibition as potential treatment for Alzheimer's disease.
Stotani S; Giordanetto F; Medda F
Future Med Chem; 2016 Apr; 8(6):681-96. PubMed ID: 27073990
[TBL] [Abstract][Full Text] [Related]
16. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
[TBL] [Abstract][Full Text] [Related]
17. Toluidine blue O modifies hippocampal amyloid pathology in a transgenic mouse model of Alzheimer's disease.
Yuksel M; Biberoglu K; Onder S; Akbulut KG; Tacal O
Biochimie; 2018 Mar; 146():105-112. PubMed ID: 29248542
[TBL] [Abstract][Full Text] [Related]
18. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
[TBL] [Abstract][Full Text] [Related]
20. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies.
Ferrer I; Gomez-Isla T; Puig B; Freixes M; Ribé E; Dalfó E; Avila J
Curr Alzheimer Res; 2005 Jan; 2(1):3-18. PubMed ID: 15977985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
